Starting from clinical needs
develop good medicines that are accessible to the general public
In January, the company was honored on Deloitte China's "Rising Star" list.
In April, the company was awarded the Third Prize at the 2025 "Rong Piao Cup" Innovation Competition.
In May, SN2001 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA).
In May, the company was selected as one of the first batch of enterprises on the "Golden Panda Future Star" list in Chengdu High-Tech Zone.
In July, the company was recognized as a Specialized, Sophisticated, Distinctive, and Innovative Small and Medium-sized Enterprise in Sichuan Province and won the Excellence Award at the 9th "Maker China" Pharmaceutical and Health Small and Medium-sized Enterprises Innovation and Entrepreneurship Competition.
In September, the Guangzhou subsidiary was established and moved into the BeiGene Innovation Center (BIC).
In July, Launched ChimiVac (u.s.Subsidiary) in NewYork.
In June, ChimigenBio was founded in the Tianfu International Bio-Town.
In November, the company completed an angel round of financing exceeding 100 million yuan.
Chimigen Biomedical (Chengdu) Co., Ltd.
1601, Tower F2, Chengdu Tianfu International Bio-Town, Chengdu, Sichuan
Tel：028-60610771
E-mail：contact@chimigen.com
Copyright© 2025 Chimigen Biomedical (Chengdu) Co., Ltd.
